Noemi Guemes
Madrid, 28040, Spain
NCT Number: NCT06431841
Phase IV clinical trial to evaluate whether there is a significant difference in the control of myopia progression in myopic children treated with 0.025% atropine and DIMS spectacle lenses compared to 0.025% atropine and single vision (SV) lenses. Open-label, randomized, parallel clinical trial with 2 arms, involving 111 patients in total. The primary efficacy endpoint will be the change in cycloplegic spherical equivalent refraction (SER) and axial length (AL) compared to baseline values.
This study is active but is not currently recruiting participants.
Notify Me4 year–16 year
All sexes
Interventional
Phase 4
Madrid, 28040, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Atropine 0,025% (1 drop per day)
Use of peripheral defocus lenses with DIMS technology, the design of which simultaneously introduces myopic defocus and provides clear vision to the wearer at all viewing distances.
Use of monofocal lenses.
Time frame: 2 years (24 months)
Cycloplegic spherical equivalent refraction (SER) change
Time frame: 2 years (24 months)
Axial length (AL) change
This study is active but is not currently recruiting participants.
Notify MeHospital San Carlos, Madrid
Other
Postmarketing Parallel Randomized Clinical Trial to Determine the Efficacy and Safety of Atropine and DIMS Lenses in the Control of Myopia in a Pediatric Population.
Acronym: ASPECT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05886348
Eye Diseases, Myopia
Beijing, China
View Trial DetailsNCT06358755
Eye Diseases, Myopia
Hong Kong
View Trial DetailsNCT07773753
Eye Diseases, Myopia
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07790640
Eye Diseases, Myopia
Incheon, South Korea
View Trial Details